Charles Klein

Chuck is a first-chair trial lawyer with almost 30 years of experience who litigates significant patent, antitrust, and commercial disputes. He is the litigation office head in Washington, D.C. and was a longtime member of the firm’s Executive Committee, co-chaired the firm’s Intellectual Property Practice, and chaired the firm’s Commercial Litigation Practice. IAM, which ranks him in the Gold tier, described him as a “talisman for major pharmaceutical and biotechnology businesses” who is “no stranger to billion-dollar cases.” Managing Intellectual Property likewise recognized him as an “IP Star.” Seven of Chuck’s first-chair victories (including three trial wins) have been mentioned in the “Litigator of the Week” column published by The American Lawyer.

Chuck has extensive experience representing clients in the pharmaceutical and biotechnology industries. This includes litigating billion-dollar patent and antitrust issues, such as representing drug manufacturers as lead counsel in high-stakes patent proceedings related to mRNA technology, the Biologics Price Competition and Innovation Act (BPCIA), and the Hatch-Waxman Act.

Chuck also is an accomplished appellate lawyer with a long history of achieving successful appellate outcomes, including multiple reversals. He has argued more than 15 appeals before various federal and state appellate courts, including the Federal Circuit, D.C. Circuit, Third Circuit, and Seventh Circuit, among others. He also has prepared successful merits and amicus briefs filed in the U.S. Supreme Court.

Chuck’s commercial litigation experience also is extensive, and he has participated in several internal investigations, including the high-profile internal investigation and related litigation concerning the compensation of former NYSE Chairman and CEO Richard A. Grasso. In connection with that matter, he deposed some of the most sophisticated witnesses in American politics and business, including Leon Panetta and the CEOs of major Wall Street firms.